GeoWealth Management LLC Sells 830 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

GeoWealth Management LLC lessened its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 10.4% during the fourth quarter, Holdings Channel.com reports. The fund owned 7,129 shares of the biopharmaceutical company’s stock after selling 830 shares during the period. GeoWealth Management LLC’s holdings in Gilead Sciences were worth $659,000 at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of the company. HHM Wealth Advisors LLC grew its stake in shares of Gilead Sciences by 118.5% in the fourth quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 154 shares during the last quarter. YANKCOM Partnership bought a new stake in shares of Gilead Sciences in the 4th quarter worth approximately $28,000. Decker Retirement Planning Inc. bought a new stake in shares of Gilead Sciences in the 4th quarter worth approximately $29,000. Crews Bank & Trust bought a new position in shares of Gilead Sciences during the fourth quarter valued at approximately $31,000. Finally, Stephens Consulting LLC lifted its stake in Gilead Sciences by 325.0% in the fourth quarter. Stephens Consulting LLC now owns 340 shares of the biopharmaceutical company’s stock worth $31,000 after acquiring an additional 260 shares during the period. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Gilead Sciences Trading Down 0.4 %

Gilead Sciences stock opened at $104.49 on Monday. Gilead Sciences, Inc. has a one year low of $62.07 and a one year high of $119.96. The business’s fifty day moving average is $109.16 and its 200 day moving average is $97.63. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.50 and a quick ratio of 1.20. The stock has a market capitalization of $130.10 billion, a PE ratio of 282.40, a price-to-earnings-growth ratio of 0.71 and a beta of 0.32.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 EPS for the quarter, topping analysts’ consensus estimates of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. On average, sell-side analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, March 28th. Stockholders of record on Friday, March 14th were issued a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a dividend yield of 3.02%. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.77. The ex-dividend date of this dividend was Friday, March 14th. Gilead Sciences’s dividend payout ratio is presently 854.05%.

Insider Transactions at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 2,500 shares of the firm’s stock in a transaction that occurred on Tuesday, April 15th. The shares were sold at an average price of $106.40, for a total value of $266,000.00. Following the transaction, the chief financial officer now owns 168,174 shares of the company’s stock, valued at approximately $17,893,713.60. This trade represents a 1.46 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Insiders have sold a total of 302,785 shares of company stock worth $30,540,875 in the last ninety days. Insiders own 0.27% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have issued reports on GILD shares. Needham & Company LLC reissued a “hold” rating on shares of Gilead Sciences in a research report on Wednesday, February 12th. BMO Capital Markets boosted their price target on shares of Gilead Sciences from $110.00 to $115.00 and gave the company an “outperform” rating in a research report on Wednesday, February 12th. Oppenheimer lifted their price objective on Gilead Sciences from $115.00 to $132.00 and gave the company an “outperform” rating in a research report on Tuesday, March 4th. Bank of America increased their target price on Gilead Sciences from $116.00 to $126.00 and gave the stock a “buy” rating in a research report on Wednesday, March 5th. Finally, Wells Fargo & Company lifted their price target on Gilead Sciences from $120.00 to $140.00 and gave the company an “overweight” rating in a research report on Wednesday, March 5th. Eleven equities research analysts have rated the stock with a hold rating, fifteen have given a buy rating and four have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $105.12.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.